Nano-X Cardiac AI Hits 92% Accuracy; First Site Billing $200-$700 per Scan

For health IT and imaging leaders, Nano-X matters less for its $40.7 million impairment and more for its clinical and reimbursement milestones. Cedars-Sinai found the cardiac AI matched standard-of-care aortic valve calcification assessments more than 92% of the time, while the first Nanox Imaging Network site is already billing insurers $200-$700 per claim. With a Medicare code for coronary artery calcium analysis now in effect, Nano-X is moving from validation toward a reimbursable clinical workflow.

On September 9, 2026, Nano-X Imaging (NASDAQ: NNOX) delivered a second-quarter earnings report that crystallized both the promise and the peril of its attempt to reshape medical imaging. Revenue climbed 37% year over year to $4.2 million for the quarter ended June 30, but the company also booked a $40.7 million impairment charge and disclosed that its cash pile had shrunk by nearly half in six months. The blunt message from management was that growth is real, yet the cash clock is ticking. In response, Nano-X is stripping down its cost structure, outsourcing chip manufacturing, cutting headcount across two continents, and leaning harder on outside distributors to get its X-ray systems into clinics before capital runs out.

“

Cedars-Sinai found the cardiac AI matched standard-of-care aortic valve calcification assessments more than 92% of the time, while the first Nanox Imaging Network site is already billing insurers $200-$700 per claim.

The reported revenue growth needs careful interpretation. The largest driver was the consolidation of the Nanox Health IT business acquired on November 19, 2025, meaning a meaningful portion of the 37% top-line increase is inorganic. Teleradiology, still the steadiest part of the operation, grew 14% year over year to $3 million on an expanded client list and the renewal of a multinational aerospace contract. The AI and software line added $1 million during the quarter, supported by five new installations and pilot programs launched across the United States and India. Those are modest absolute figures for a company attempting to challenge incumbent imaging giants, but they represent early commercial signals in a highly regulated, capital-intensive market.

Perhaps the most consequential number in the release is also the smallest. Nano-X's first Nanox Imaging Network site in Philadelphia has begun scanning patients and collecting insurance payments of $200 to $700 per claim. Management believes a fully utilized site could generate $500,000 to $1 million in annual revenue, built around segments such as workers' compensation and concierge medicine where reimbursement rates tend to run higher. Ten signed U.S. distribution partnerships now supplement the direct sales team, suggesting a capital-light channel strategy aimed at accelerating site deployment without requiring the company to fund every location itself. If multiple locations can reach utilization, the imaging network model could shift Nano-X from a hardware vendor into a recurring-revenue service provider.

Reimbursement and clinical validation are equally important for the forward story. A new Medicare code covering algorithmic analysis of coronary artery calcium became effective April 1, 2026, opening a reimbursement pathway for the company's cardiac AI tool. A Cedars-Sinai pilot study found that the AI matched standard-of-care assessments of aortic valve calcification more than 92% of the time. That level of concordance is a meaningful signal for clinicians and hospital administrators who need evidence before adopting new imaging software. It also gives Nano-X a differentiated asset beyond commodity X-ray hardware, with a reimbursement tailwind that could support higher-margin software revenue over time.